Tenax Therapeutics, Inc. Stock News
$1.69
0.00%
Nasdaq, Nov 11, 02:17 pm EST.
Market open.
Tenax Therapeutics, Inc. Stock News
LOS ANGELES, Nov. 9, 2026 /PRNewswire/ -- Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Tenax Therapeutics, Inc. ("Tenax" or "the Company") (NASDAQ: TENX) for violations of the securities laws. INVESTIGATION DETAILS: The investigation focuses on whether the Company issued false and/or misl...
LOS ANGELES, Nov. 6, 2026 /PRNewswire/ -- Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Tenax Therapeutics, Inc. ("Tenax" or "the Company") (NASDAQ: TENX) for violations of the securities laws. INVESTIGATION DETAILS: The investigation focuses on whether the Company issued false and/or misl...
Completed Statistical Analyses of LEVEL Yielded a Predictive Enrichment Strategy Being Applied in Amended LEVEL-2 Protocol Company Has Been Granted a Type C Meeting with the FDA CHAPEL HILL, N.C., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”) today reported financial results for the quarter ended September 30, 2026 ...
In patients with a baseline 6MWD below the trial median of 333 meters, treatment with TNX-103 resulted in a 26.3-meter improvement compared to placebo (p = 0.0112)
LOS ANGELES--(BUSINESS WIRE)---- $TENX--TENX Investors Have Opportunity to Join Tenax Therapeutics, Inc. Fraud Investigation with SBS Law.
Tenax Therapeutics said on Monday its experimental heart drug failed to meet the main goal of a late-stage study.
TNX-103 did not meet statistical significance on the primary endpoint of improvement in 6-minute walk distance versus placebo
Company expects to report topline data from Phase 3 LEVEL clinical trial in August 2026 CHAPEL HILL, N.C., July 31, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”) today reported financial results for the quarter ended June 30, 2026 and provided an update on its corporate progress.
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
